Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS

Summary

The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis at one year and long-term follow-up in liver cirrhotic patients after laparoscopic splenectomy and azygoportal disconnection.

Eligibility

Inclusion Criteria:

1. A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.
2. Splenomegaly with secondary hypersplenism.
3. Bleeding portal hypertension.
4. No evidence of portal vein thrombosis (PVT) or spleno-mesenteric thrombosis by ultrasound evaluation and angio-CT prior to surgery.
5. Underwent laparoscopic splenectomy and azygoportal disconnection (LSD) at our center.
6. Received routine aspirin anticoagulation (2.5 mg twice daily) immediately after surgery.
7. Had no imaging evidence (Doppler ultrasound or CT) of PVT during postoperative months 6 to 12.
8. Developed de novo PVT after 12 months post-surgery.
9. Provided informed consent to participate in the study.

Exclusion Criteria:

1. Hepatocellular carcinoma or any other malignancy,
2. Hypercoagulable state other than the liver disease related
3. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.
4. Child - Pugh C
5. Recent peptic ulcer disease
6. History of Hemorrhagic stroke
7. Pregnancy.
8. Uncontrolled Hypertension
9. Human immunodeficiency virus (HIV) infection

Conditions5

Interventions2

Browse More Trials